Dear Vein Therapy News clients: The health and safety of our clients and employees is our highest priority. In normal times, we would see you at medical conferences and site visits. Because of the danger of contracting or spreading the coronavirus disease COVID-19, many of us will not be

AngioDynamics Inc., a provider of innovative, minimally invasive medical devices for oncology, vascular access and peripheral vascular disease, has agreed to sell its NAMIC fluid management portfolio to Medline Industries Inc. for $167.5 million, subject to customary closing conditions including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The

  Merz North America Inc. has regained exclusive distribution of Asclera (polidocanol) Injection in the United States to all healthcare practitioners and phlebologists treating varicose veins. Also effective April 8, AngioDynamics Inc. is no longer an authorized distributor of Asclera. All HCPs will now be able to purchase Asclera directly

  Editor’s Note: This June 3 article is an update to an article in the June/July issue of Vein Therapy News. AngioDynamics Inc. has closed the previously announced sale of its NAMIC fluid management portfolio to Medline Industries Inc. on May 31, 2019 for $167.5 million. AngioDynamics has used a portion

  When the NASDAQ Stock Market closing bell rang on May 28, it was AngioDynamics’s three most tenured employees who were doing the honors. The May 28 honor commemorated the company’s 15th anniversary on the exchange.   “NASDAQ has provided AngioDynamics with a robust platform to access the public equity